Suppr超能文献

从营养过剩到肝损伤:AMP 激活的蛋白激酶在非酒精性脂肪性肝病中的作用。

From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.

机构信息

Department of Medicine, University of California San Diego, La Jolla, California, USA.

Department of Medicine, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

出版信息

J Biol Chem. 2020 Aug 21;295(34):12279-12289. doi: 10.1074/jbc.REV120.011356. Epub 2020 Jul 10.

Abstract

Nonalcoholic fatty liver diseases (NAFLDs), especially nonalcoholic steatohepatitis (NASH), have become a major cause of liver transplant and liver-associated death. However, the pathogenesis of NASH is still unclear. Currently, there is no FDA-approved medication to treat this devastating disease. AMP-activated protein kinase (AMPK) senses energy status and regulates metabolic processes to maintain homeostasis. The activity of AMPK is regulated by the availability of nutrients, such as carbohydrates, lipids, and amino acids. AMPK activity is increased by nutrient deprivation and inhibited by overnutrition, inflammation, and hypersecretion of certain anabolic hormones, such as insulin, during obesity. The repression of hepatic AMPK activity permits the transition from simple steatosis to hepatocellular death; thus, activation might ameliorate multiple aspects of NASH. Here we review the pathogenesis of NAFLD and the impact of AMPK activity state on hepatic steatosis, inflammation, liver injury, and fibrosis during the transition of NAFL to NASH and liver failure.

摘要

非酒精性脂肪性肝病(NAFLD),尤其是非酒精性脂肪性肝炎(NASH),已成为肝移植和与肝相关死亡的主要原因。然而,NASH 的发病机制仍不清楚。目前,还没有 FDA 批准的药物来治疗这种毁灭性的疾病。腺苷酸活化蛋白激酶(AMPK)感知能量状态并调节代谢过程以维持体内平衡。AMPK 的活性受营养物质(如碳水化合物、脂质和氨基酸)的可用性调节。营养物质缺乏会增加 AMPK 的活性,而肥胖时营养过剩、炎症和某些合成代谢激素(如胰岛素)的过度分泌会抑制 AMPK 的活性。肝 AMPK 活性的抑制允许从单纯性脂肪变性向肝细胞死亡的转变;因此,激活可能改善 NASH 的多个方面。在这里,我们综述了 NAFLD 的发病机制以及 AMPK 活性状态对从单纯性脂肪变性向 NASH 和肝衰竭转变过程中肝脂肪变性、炎症、肝损伤和纤维化的影响。

相似文献

1
From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.
J Biol Chem. 2020 Aug 21;295(34):12279-12289. doi: 10.1074/jbc.REV120.011356. Epub 2020 Jul 10.
2
Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.
J Clin Invest. 2018 Dec 3;128(12):5335-5350. doi: 10.1172/JCI63562. Epub 2018 Oct 29.
5
An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.
Science. 2020 Feb 7;367(6478):652-660. doi: 10.1126/science.aay0542.
6
FTZ attenuates liver steatosis and fibrosis in the minipigs with type 2 diabetes by regulating the AMPK signaling pathway.
Biomed Pharmacother. 2021 Jun;138:111532. doi: 10.1016/j.biopha.2021.111532. Epub 2021 Apr 3.
8
Treatment of nonalcoholic fatty liver disease: role of AMPK.
Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E730-E740. doi: 10.1152/ajpendo.00225.2016. Epub 2016 Aug 30.
10
[Research progress on AMPK activation in nonalcoholic fatty liver disease].
Zhonghua Gan Zang Bing Za Zhi. 2023 Nov 20;31(11):1220-1223. doi: 10.3760/cma.j.cn501113-20231107-00176.

引用本文的文献

1
RXR modulates hepatic stellate cell activation and liver fibrosis by targeting CaMKK-AMPK axis.
Acta Pharm Sin B. 2025 Jul;15(7):3611-3631. doi: 10.1016/j.apsb.2025.05.023. Epub 2025 May 26.
2
Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances.
Front Oncol. 2025 Apr 8;15:1526206. doi: 10.3389/fonc.2025.1526206. eCollection 2025.
4
Research progress on AMPK in the pathogenesis and treatment of MASLD.
Front Immunol. 2025 Mar 11;16:1558041. doi: 10.3389/fimmu.2025.1558041. eCollection 2025.
5
Cinnabarinic acid protects against metabolic dysfunction-associated steatohepatitis by activating aryl hydrocarbon receptor-dependent AMPK signaling.
Am J Physiol Gastrointest Liver Physiol. 2025 Apr 1;328(4):G433-G447. doi: 10.1152/ajpgi.00337.2024. Epub 2025 Mar 10.
7
The role and function of lncRNA in ageing-associated liver diseases.
RNA Biol. 2025 Dec;22(1):1-8. doi: 10.1080/15476286.2024.2440678. Epub 2024 Dec 19.
8
Signaling pathways that activate hepatic stellate cells during liver fibrosis.
Front Med (Lausanne). 2024 Sep 18;11:1454980. doi: 10.3389/fmed.2024.1454980. eCollection 2024.

本文引用的文献

1
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.
Cell Metab. 2020 May 5;31(5):892-908.e11. doi: 10.1016/j.cmet.2020.04.011.
2
Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis.
Immunity. 2020 Jun 16;52(6):1057-1074.e7. doi: 10.1016/j.immuni.2020.04.001. Epub 2020 May 1.
3
AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control.
Cell Metab. 2020 Mar 3;31(3):472-492. doi: 10.1016/j.cmet.2020.01.015.
4
An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.
Science. 2020 Feb 7;367(6478):652-660. doi: 10.1126/science.aay0542.
5
Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis.
Cell Metab. 2020 Jan 7;31(1):189-206.e8. doi: 10.1016/j.cmet.2019.10.014. Epub 2019 Nov 21.
7
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
Expert Opin Investig Drugs. 2020 Feb;29(2):135-141. doi: 10.1080/13543784.2020.1668374. Epub 2019 Sep 19.
8
A novel AMPK activator improves hepatic lipid metabolism and leukocyte trafficking in experimental hepatic steatosis.
J Pharmacol Sci. 2019 Jun;140(2):153-161. doi: 10.1016/j.jphs.2019.05.008. Epub 2019 Jun 4.
10
Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD.
Cell Rep. 2019 Jan 2;26(1):192-208.e6. doi: 10.1016/j.celrep.2018.12.036.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验